

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

CHANGE OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of HBM Holdings Limited (the “**Company**”) hereby announces that Ms. Yifan Gao (高一帆) (“**Ms. Gao**”) has ceased to be a joint company secretary of the Company (the “**Joint Company Secretary**”) under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) with effect from 26 May 2025 due to the change of her work arrangements in the Company.

Ms. Gao has confirmed that she has no disagreement with the Board, and there is no matter in relation to her cessation as the Joint Company Secretary that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

Following the cessation of Ms. Gao, the other current Joint Company Secretary, Mr. Wing Yat Christopher Lui, who possesses the requisite qualifications and experience of a company secretary as required by Rule 3.28 of the Listing Rules, will remain in office and act as the sole company secretary of the Company.

The Board would like to take this opportunity to express its gratitude to Ms. Gao for her valuable contributions to the Company during her tenure as the Joint Company Secretary.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 30 May 2025

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.